{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:18:45Z","timestamp":1725322725513},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"DOI":"10.7759\/cureus.68461","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:14:46Z","timestamp":1725290086000},"source":"Crossref","is-referenced-by-count":0,"title":["A Review of Neoadjuvant Therapy and the Watch-and-Wait Protocol in Rectal Cancer: Current Evidence and Future Directions"],"prefix":"10.7759","author":[{"given":"Iulian M","family":"Slavu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavian","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florin","family":"Filipoiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Tulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca Monica","family":"Macovei Oprescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Dima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulian A","family":"Dogaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Tulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/00015458.2020.1745529","article-title":"Total mesorectal excision - 40 years of standard of rectal cancer surgery","volume":"120","author":"Votava J","year":"2020","unstructured":"Votava J, Kachlik D, Hoch J. Total mesorectal excision - 40 years of standard of rectal cancer surgery. Acta Chir Belg. 2020, 120:286-90. 10.1080\/00015458.2020.1745529","journal-title":"Acta Chir Belg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama A","year":"2004","unstructured":"Habr-Gama A, Perez RO, Nadalin W, et al.. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004, 240:711-7; discussion 717-8. 10.1097\/01.sla.0000141194.27992.32","journal-title":"Ann Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.12.012","article-title":"Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control","volume":"88","author":"Habr-Gama A","year":"2014","unstructured":"Habr-Gama A, Gama-Rodrigues J, S\u00e3o Juli\u00e3o GP, Proscurshim I, Sabbagh C, Lynn PB, Perez RO. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014, 88:822-8. 10.1016\/j.ijrobp.2013.12.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra EA","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GA, et al.. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023, 278:e766-72. 10.1097\/SLA.0000000000005799","journal-title":"Ann Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","volume":"27","author":"Bujko K","year":"2016","unstructured":"Bujko K, Wyrwicz L, Rutkowski A, et al.. Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016, 27:834-42. 10.1093\/annonc\/mdw062","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.8702","article-title":"Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer","volume":"99","author":"Martin ST","year":"2012","unstructured":"Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012, 99:918-28. 10.1002\/bjs.8702","journal-title":"Br J Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis","volume":"2","author":"Dossa F","year":"2017","unstructured":"Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017, 2:501-13. 10.1016\/S2468-1253(17)30074-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk MJM","year":"2018","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E, et al.. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018, 391:2537-45. 10.1016\/S0140-6736(18)31078-X","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.521","article-title":"The International Watch & Wait database (IWWD) for rectal cancer: an update","volume":"35","author":"Valk MV","year":"2017","unstructured":"Valk MV, International Watch and Wait Database Consortium. The International Watch & Wait database (IWWD) for rectal cancer: an update. J Clin Oncol. 2017, 35:10-1200. 10.1200\/JCO.2017.35.4_suppl.521","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad051","article-title":"Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD)","volume":"110","author":"Temmink SJ","year":"2023","unstructured":"Temmink SJ, Peeters KC, Bahadoer RR, et al.. Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD). Br J Surg. 2023, 110:676-84. 10.1093\/bjs\/znad051","journal-title":"Br J Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones R","year":"2017","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, R\u00f6del C, Cervantes A, Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv22-40. 10.1093\/annonc\/mdx224","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer R","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, et al.. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004, 351:1731-40. 10.1056\/NEJMoa040694","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24622","article-title":"Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome","volume":"115","author":"Chang GJ","year":"2009","unstructured":"Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009, 115:5432-40. 10.1002\/cncr.24622","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7901","article-title":"Neoadjuvant treatment response as an early response indicator for patients with rectal cancer","volume":"30","author":"Park IJ","year":"2012","unstructured":"Park IJ, You YN, Agarwal A, et al.. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012, 30:1770-6. 10.1200\/JCO.2011.39.7901","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5858\/133.10.1539","article-title":"Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum","volume":"133","author":"Washington MK","year":"2009","unstructured":"Washington MK, Berlin J, Branton P, et al.. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009, 133:1539-51. 10.5858\/133.10.1539","journal-title":"Arch Pathol Lab Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1503\/cjs.005822","article-title":"Total neoadjuvant therapy for rectal cancer: a guide for surgeons","volume":"66","author":"Johnson GG","year":"2023","unstructured":"Johnson GG, Park J, Helewa RM, Goldenberg BA, Nashed M, Hyun E. Total neoadjuvant therapy for rectal cancer: a guide for surgeons. Can J Surg. 2023, 66:E196-201. 10.1503\/cjs.005822","journal-title":"Can J Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy T","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, et al.. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:702-15. 10.1016\/S1470-2045(21)00079-6","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3504","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial","volume":"41","author":"Conroy T","year":"2023","unstructured":"Conroy T. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2023, 41:3504. 10.1200\/JCO.2023.41.17_suppl.LBA3504","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00900-9","article-title":"Future direction of total neoadjuvant therapy for locally advanced rectal cancer","volume":"21","author":"Kagawa Y","year":"2024","unstructured":"Kagawa Y, Smith JJ, Fokas E, et al.. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024, 21:444-55. 10.1038\/s41575-024-00900-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer RR","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, et al.. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:29-42. 10.1016\/S1470-2045(20)30555-6","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij FS","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, et al.. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024, 42:500-6. 10.1200\/JCO.23.01208","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12","volume":"37","author":"Fokas E","year":"2019","unstructured":"Fokas E, Allg\u00e4uer M, Polat B, et al.. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12. J Clin Oncol. 2019, 37:3212-22. 10.1200\/JCO.19.00308","journal-title":"J Clin Oncol"},{"key":"ref23","unstructured":"Neoadjuvant therapy for rectal adenocarcinoma. (2024). https.\/\/www.uptodate.com\/contents\/neoadjuvant-therapy-for-rectal-adenocarcinoma."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford K","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, et al.. Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol. 2023, 41:2181-90. 10.1200\/JCO.22.01351","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2210175","article-title":"Prevalence of mismatch-repair deficiency in rectal adenocarcinomas","volume":"387","author":"Papke DJ Jr","year":"2022","unstructured":"Papke DJ Jr, Yurgelun MB, Noffsinger AE, Turner KO, Genta RM, Redston M. Prevalence of mismatch-repair deficiency in rectal adenocarcinomas. N Engl J Med. 2022, 387:1714-6. 10.1056\/NEJMc2210175","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek A","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, et al.. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022, 386:2363-76. 10.1056\/NEJMoa2201445","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi M","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, et al.. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020, 26:566-76. 10.1038\/s41591-020-0805-8","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30218-2","article-title":"Watch-and-wait approach for rectal cancer: concepts of a subject-specific method","volume":"2","author":"Renehan AG","year":"2017","unstructured":"Renehan AG, Malcomson L, Emsley R. Watch-and-wait approach for rectal cancer: concepts of a subject-specific method. Lancet Gastroenterol Hepatol. 2017, 2:627. 10.1016\/S2468-1253(17)30218-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar J","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, et al.. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022, 40:2546-56. 10.1200\/JCO.22.00032","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.11.017","article-title":"Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme","volume":"132","author":"van der Sande ME","year":"2019","unstructured":"van der Sande ME, Hupkens BJ, Berb\u00e9e M, et al.. Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. Radiother Oncol. 2019, 132:79-84. 10.1016\/j.radonc.2018.11.017","journal-title":"Radiother Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn.441530-20200224-00081","article-title":"Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy [Article in Chinese]","volume":"23","author":"Wang XH","year":"2020","unstructured":"Wang XH, Zhou CJ, Zhang S, et al.. Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy [Article in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2020, 23:266-73. 10.3760\/cma.j.cn.441530-20200224-00081","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s44178-023-00024-1","article-title":"\u201cWatch and wait\u201d strategy after neoadjuvant chemoradiotherapy in rectal cancer: opportunities and challenges","volume":"2","author":"Yang Y","year":"2023","unstructured":"Yang Y, Huang A, Sun Z, Hong HP, Kim NK, Gu J. \u201cWatch and wait\u201d strategy after neoadjuvant chemoradiotherapy in rectal cancer: opportunities and challenges. Holist Integr Oncol. 2023, 2:4. 10.1007\/s44178-023-00024-1","journal-title":"Holist Integr Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003286","article-title":"Conditional survival in patients with rectal cancer and complete clinical response managed by watch and wait after chemoradiation: recurrence risk over time","volume":"272","author":"S\u00e3o Juli\u00e3o GP","year":"2020","unstructured":"S\u00e3o Juli\u00e3o GP, Karagkounis G, Fernandez LM, et al.. Conditional survival in patients with rectal cancer and complete clinical response managed by watch and wait after chemoradiation: recurrence risk over time. Ann Surg. 2020, 272:138-44. 10.1097\/SLA.0000000000003286","journal-title":"Ann Surg"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1632-z","article-title":"Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management","volume":"15","author":"Smith JJ","year":"2015","unstructured":"Smith JJ, Chow OS, Gollub MJ, et al.. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015, 15:767. 10.1186\/s12885-015-1632-z","journal-title":"BMC Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq170","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21 Suppl 5","author":"Glimelius B","year":"2010","unstructured":"Glimelius B, P\u00e5hlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21 Suppl 5:v82-6. 10.1093\/annonc\/mdq170","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001338","article-title":"Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!","volume":"62","author":"Habr-Gama A","year":"2019","unstructured":"Habr-Gama A, S\u00e3o Juli\u00e3o GP, Fernandez LM, et al.. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!. Dis Colon Rectum. 2019, 62:802-8. 10.1097\/DCR.0000000000001338","journal-title":"Dis Colon Rectum"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101774","article-title":"Watch and wait: why, to whom and how","volume":"43","author":"Cerd\u00e1n-Santacruz C","year":"2022","unstructured":"Cerd\u00e1n-Santacruz C, Vailati BB, S\u00e3o Juli\u00e3o GP, Habr-Gama A, Perez RO. Watch and wait: why, to whom and how. Surg Oncol. 2022, 43:101774. 10.1016\/j.suronc.2022.101774","journal-title":"Surg Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082873","article-title":"Watch and wait approach for rectal cancer","volume":"12","author":"Cerdan-Santacruz C","year":"2023","unstructured":"Cerdan-Santacruz C, S\u00e3o Juli\u00e3o GP, Vailati BB, Corbi L, Habr-Gama A, Perez RO. Watch and wait approach for rectal cancer. J Clin Med. 2023, 12:2873. 10.3390\/jcm12082873","journal-title":"J Clin Med"},{"key":"ref39","article-title":"Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided?","volume":"60","author":"Ayloor Seshadri R","year":"2013","unstructured":"Ayloor Seshadri R, Kondaveeti SS, Jayanand SB, et al.. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided?. Hepatogastroenterology. 2013, 60:410-4.","journal-title":"Hepatogastroenterology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.08.156","article-title":"Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study","volume":"41","author":"Araujo RO","year":"2015","unstructured":"Araujo RO, Valad\u00e3o M, Borges D, et al.. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015, 41:1456-63. 10.1016\/j.ejso.2015.08.156","journal-title":"Eur J Surg Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2018.12.007","article-title":"Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy","volume":"42","author":"Yeom SS","year":"2019","unstructured":"Yeom SS, Lee SY, Kim CH, Kim YJ, Nam TK, Kim HR. Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy. Asian J Surg. 2019, 42:823-31. 10.1016\/j.asjsur.2018.12.007","journal-title":"Asian J Surg"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31820b8d52","article-title":"Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study","volume":"253","author":"Taylor FG","year":"2011","unstructured":"Taylor FG, Quirke P, Heald RJ, et al.. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011, 253:711-9. 10.1097\/SLA.0b013e31820b8d52","journal-title":"Ann Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701697720","article-title":"Preoperative staging of rectal cancer","volume":"47","author":"Smith N","year":"2008","unstructured":"Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 2008, 47:20-31. 10.1080\/02841860701697720","journal-title":"Acta Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.10.019","article-title":"The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis","volume":"159","author":"de Jong EA","year":"2016","unstructured":"de Jong EA, ten Berge JC, Dwarkasing RS, Rijkers AP, van Eijck CH. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis. Surgery. 2016, 159:688-99. 10.1016\/j.surg.2015.10.019","journal-title":"Surgery"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31822b8cfa","article-title":"Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer","volume":"254","author":"Garcia-Aguilar J","year":"2011","unstructured":"Garcia-Aguilar J, Chen Z, Smith DD, et al.. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011, 254:486-92; discussion 492-3. 10.1097\/SLA.0b013e31822b8cfa","journal-title":"Ann Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/his.14710","article-title":"Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature","volume":"81","author":"Swets M","year":"2022","unstructured":"Swets M, Graham Martinez C, van Vliet S, et al.. Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature. Histopathology. 2022, 81:352-62. 10.1111\/his.14710","journal-title":"Histopathology"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-017-5026-2","article-title":"Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting","volume":"28","author":"Beets-Tan RG","year":"2018","unstructured":"Beets-Tan RG, Lambregts DM, Maas M, et al.. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018, 28:1465-75. 10.1007\/s00330-017-5026-2","journal-title":"Eur Radiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2272011747","article-title":"Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison","volume":"227","author":"Brown G","year":"2003","unstructured":"Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, Williams GT. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003, 227:371-7. 10.1148\/radiol.2272011747","journal-title":"Radiology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-023-03893-2","article-title":"Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel","volume":"48","author":"Lee S","year":"2023","unstructured":"Lee S, Kassam Z, Baheti AD, et al.. Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel. Abdom Radiol (NY). 2023, 48:2792-806. 10.1007\/s00261-023-03893-2","journal-title":"Abdom Radiol (NY)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4687-9","article-title":"Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment","volume":"22","author":"Maas M","year":"2015","unstructured":"Maas M, Lambregts DM, Nelemans PJ, et al.. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015, 22:3873-80. 10.1245\/s10434-015-4687-9","journal-title":"Ann Surg Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.09.026","article-title":"Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials","volume":"154","author":"Gambacorta MA","year":"2021","unstructured":"Gambacorta MA, Masciocchi C, Chiloiro G, et al.. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol. 2021, 154:154-60. 10.1016\/j.radonc.2020.09.026","journal-title":"Radiother Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","volume":"16","author":"Garcia-Aguilar J","year":"2015","unstructured":"Garcia-Aguilar J, Chow OS, Smith DD, et al.. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015, 16:957-66. 10.1016\/S1470-2045(15)00004-2","journal-title":"Lancet Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-021-02440-9","article-title":"T2-weighted, apparent diffusion coefficient and 18F-FDG PET histogram analysis of rectal cancer after preoperative chemoradiotherapy","volume":"25","author":"Crim\u00ec F","year":"2021","unstructured":"Crim\u00ec F, Stramare R, Spolverato G, et al.. T2-weighted, apparent diffusion coefficient and 18F-FDG PET histogram analysis of rectal cancer after preoperative chemoradiotherapy. Tech Coloproctol. 2021, 25:569-77. 10.1007\/s10151-021-02440-9","journal-title":"Tech Coloproctol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.06.005","article-title":"Early prediction of response by 18F-FDG PET\/CT during preoperative therapy in locally advanced rectal cancer: a systematic review","volume":"40","author":"Maffione AM","year":"2014","unstructured":"Maffione AM, Chondrogiannis S, Capirci C, et al.. Early prediction of response by 18F-FDG PET\/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014, 40:1186-94. 10.1016\/j.ejso.2014.06.005","journal-title":"Eur J Surg Oncol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-014-0938-2","article-title":"Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET\/CT in patients with rectal cancer","volume":"29","author":"Rendl G","year":"2015","unstructured":"Rendl G, Rettenbacher L, Holzmannhofer J, et al.. Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET\/CT in patients with rectal cancer. Ann Nucl Med. 2015, 29:284-94. 10.1007\/s12149-014-0938-2","journal-title":"Ann Nucl Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3393\/ac.2019.04.22","article-title":"Clinical outcomes of patients with locally advanced rectal cancer with persistent circumferential resection margin invasion after preoperative chemoradiotherapy","volume":"35","author":"Kim CH","year":"2019","unstructured":"Kim CH, Yeom SS, Kwak HD, Lee SY, Ju JK, Kim YJ, Kim HR. Clinical outcomes of patients with locally advanced rectal cancer with persistent circumferential resection margin invasion after preoperative chemoradiotherapy. Ann Coloproctol. 2019, 35:72-82. 10.3393\/ac.2019.04.22","journal-title":"Ann Coloproctol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3393\/ac.2019.04.22.1","article-title":"Oncologic outcomes in patients who undergo neoadjuvant chemoradiotherapy and total mesorectal excision for locally advanced rectal cancer: a 14-year experience in a single institution","volume":"35","author":"Kim MJ","year":"2019","unstructured":"Kim MJ, Jeong SY, Park JW, Ryoo SB, Cho SS, Lee KY, Park KJ. Oncologic outcomes in patients who undergo neoadjuvant chemoradiotherapy and total mesorectal excision for locally advanced rectal cancer: a 14-year experience in a single institution. Ann Coloproctol. 2019, 35:83-93. 10.3393\/ac.2019.04.22.1","journal-title":"Ann Coloproctol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.2172","article-title":"Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy","volume":"154","author":"Ogura A","year":"2019","unstructured":"Ogura A, Konishi T, Beets GL, et al.. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy. JAMA Surg. 2019, 154:e192172. 10.1001\/jamasurg.2019.2172","journal-title":"JAMA Surg"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.10.029","article-title":"EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review","volume":"40","author":"Tudyka V","year":"2014","unstructured":"Tudyka V, Blomqvist L, Beets-Tan RG, et al.. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2014, 40:469-75. 10.1016\/j.ejso.2013.10.029","journal-title":"Eur J Surg Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/codi.16034","article-title":"Selected stage IV rectal cancer patients managed by the watch-and-wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery?","volume":"24","author":"Custers PA","year":"2022","unstructured":"Custers PA, Hupkens BJ, Grotenhuis BA, Kuhlmann KF, Breukink SO, Beets GL, Melenhorst J. Selected stage IV rectal cancer patients managed by the watch-and-wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery?. Colorectal Dis. 2022, 24:401-10. 10.1111\/codi.16034","journal-title":"Colorectal Dis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","author":"Erlandsson J","year":"2017","unstructured":"Erlandsson J, Holm T, Pettersson D, et al.. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017, 18:336-346. 10.1016\/S1470-2045(17)30086-4","journal-title":"Lancet Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5896","article-title":"Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy","volume":"5","author":"Smith JJ","year":"2019","unstructured":"Smith JJ, Strombom P, Chow OS, et al.. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019, 5:e185896. 10.1001\/jamaoncol.2018.5896","journal-title":"JAMA Oncol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000733","article-title":"Recent trends and overall survival of young versus older adults with stage ii to iii rectal cancer treated with and without surgery in the United States, 2010-2015","volume":"43","author":"Sanford NN","year":"2020","unstructured":"Sanford NN, Dee EC, Ahn C, et al.. Recent trends and overall survival of young versus older adults with stage ii to iii rectal cancer treated with and without surgery in the United States, 2010-2015. Am J Clin Oncol. 2020, 43:694-700. 10.1097\/COC.0000000000000733","journal-title":"Am J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275072-a-review-of-neoadjuvant-therapy-and-the-watch-and-wait-protocol-in-rectal-cancer-current-evidence-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:14:53Z","timestamp":1725290093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275072-a-review-of-neoadjuvant-therapy-and-the-watch-and-wait-protocol-in-rectal-cancer-current-evidence-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.68461","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}